Next Generation Sequencing (NGS) Market Size, Growth and …€¦ · Next Generation Sequencing...
Transcript of Next Generation Sequencing (NGS) Market Size, Growth and …€¦ · Next Generation Sequencing...
1
NGS2019 – 13PFP
Next Generation Sequencing
(NGS) Market Size, Growth and
Trends (2016-2022)
– Table of Contents
September 26th,, 20195th edition
Information contained in this market report is believed to be reliable
at the time of publication. DeciBio is not soliciting any action based
on the information contained in this report. See appendix section for
complete disclosures.
2
NGS2019 – 13PFP
Agenda
• Table of Contents
3
NGS2019 – 13PFP
We forecast that the NGS manufacturer market will reach $4.4B in 2019, and
grow at 14% p.a. to $6.5B in 2022, driven by clinical applications (1 of 2)
Note: * Including third generation sequencing (single molecule NGS [e.g., Pacific Biosciences, Oxford Nanopore])
** Based on a comprehensive market model (see slide 11 in downloadable Table of Contents)
*** 4 additional players are modelled separately: ONT, BGI, QIAGEN, and Genapsys; other players (e.g., Agilent, NEB, Archer Dx) are modelled as a basket
Next Generation Sequencing (NGS)* has transformed the life sciences and diagnostics landscapes. This technology is used for
applications including human whole genome sequencing (WGS), whole exome sequencing (WES; 1-2% of the genome that
encodes proteins), targeted sequencing using panels of a few-to-thousands of genes, and expression profiling (i.e., RNA-Seq).
We forecast that the manufacturer market size will reach ~$4.4B in 2019, and grow at 14% p.a. to $6.5B in 2022, driven primarily
by adoption from clinical customers worldwide**. NGS has revolutionized not only medical research in academic laboratories and
biopharma, but also the health care landscape and applied markets (e.g., AgBio, food testing).
The fifth edition of this report reviews the market size, segmentation, growth and trends of the manufacturer NGS (i.e., excluding
NGS services [e.g., Foundation Medicine]) market. We assess the NGS market across 6 segments:
• Company: Illumina, Thermo Fisher (Ion Torrent), Roche (Kapa Bio, Genia), Pacific Biosciences, and others***
• Product Type: Instruments (including software) and Reagents (including consumables)
• Customer: Academic Basic Research, Population Studies, Biopharma R&D, Biopharma Clinical Trials, Liquid Biopsy
Clinical Trials, Clinical Diagnostics (Oncology), Clinical Diagnostics (NIPT), Clinical Diagnostics (All other), Liquid Biopsy
(Dx), Applied Markets, Industry
• Application: Human WGS, WES, Targeted Resequencing, RNA-Seq, Other
• Therapeutic Area: Genomics, Oncology, Infectious Diseases, Method Development, and Others
• Geography: U.S., Europe, China, Asia/Pacific (APAC), and Rest of the world (RoW)
For each segments, we provide the market size in 2016, 2019 and 2022, and commentary on key growth drivers and moderators.
Major factors driving future growth include:
• Accelerating adoption in clinical settings (both in clinical trial and routine testing) now representing about half of the market,
especially for clinical oncology across the patient journey from early (asymptomatic) detection (in trial stages at GRAIL,
Freenome, etc) to therapy selection (e.g., Guardant Health, Foundation Medicine), or therapy monitoring and cancer
recurrence testing (e.g., Natera)
• Increased reagent usage on an expanding instrument installed base across applications, especially for higher throughput
instruments (i.e., NovaSeq)
• Increased adoption of the technology by new customers (e.g., Applied markets such as AgBio, Biopharma for patient
stratification during clinical trials)
• Increased usage for new scientific applications built upon sequencing detection (e.g., [single cell] RNA-Seq, ChIP-Seq,
methylation studies, spatial profiling on NanoString GeoMx)
Abstract
4
NGS2019 – 13PFP
We forecast that the NGS manufacturer market will reach $4.4B in 2019, and
grow at 14% p.a. to $6.5B in 2022, driven by clinical applications (2 of 2)
Key factors moderating growth include:
• Excess capacity: previously installed instruments operating at 10-30% of capacity
• Pricing pressure has decreased cost per Gb moderating overall revenue growth, due to competitive pressure (particularly
from MGI), and the availability of more affordable instrument options (e.g., Illumina’s iSeq, Oxford Nanopore’s Flongle)
• Reimbursement uncertainty and pushback in clinical settings (due in part to lack of education even in some cases where
tests are covered by insurance companies) limiting access to the vast majority of clinical samples in the U.S.
• Out-of-pocket pay for some tests (60-80%) in China limiting adoption
• Continued bioinformatics and data analysis challenges, especially for structural variants or translational and clinical
applications (e.g., clinical variant interpretation), gating access to most potentially addressable samples
• Low growth in research funding in established markets
We also review interesting market trends, such as:
• Increased use of native long read technologies, most notably Oxford Nanopore
• Increased number (and scale) of population sequencing programs (e.g., Korea planning to sequence 1M genomes by 2029)
• Diversification of sequencing options driven by the launch of multiple new platforms by new players (e.g., BGI’s T7, Oxford
Nanopore’s PromethION, Genapsys GENIUS), and many additional companies with novel sequencers
• Consolidation of applications on increasingly differentiated platforms, based on their workflow, turnaround time and cost
(e.g., human WGS on NovaSeq, field-based pathogen sequencing on the MinION)
• Simplification of the overall workflow, with the launch of more automated instruments (e.g., S5) or automated sample
preparation instruments (e.g., Ion Chef, NeoPrep, VolTRAX), saving time, and increasing reproducibility
• Continued decentralization of sequencing runs driven by the availability of low cost desktop sequencers (e.g., MiSeq), but in
turn a centralization of sequencing volumes as high throughput platforms can cost-effectively run 10,000’s of samples
• Increasing use of service providers offering an alternative to in-house platform adoption, as many customers don’t have the
budget for or interest in large capital expenditures for such fast-evolving technologies
• Increasing number of players participating in this fast growing market, typically offering front end (sample preparation) or
backend (bioinformatics) solutions, with most targeting (clinical) oncology
• Increasing competitive intensity on dimensions others than cost per base pair (e.g., workflow, portability, clinical content)
Disclaimer: Some of the companies listed in this report may be DeciBio clients or customers
Abstract
5
NGS2019 – 13PFP
This report is divided into the following sections
Introduction 2
Abstract 3
Table of Contents 5
4th Edition: What’s New? 6
Included / Excluded Technologies 7
Definitions & Methodologies 8
NGS Competitive Landscape 65
NGS Market by Competitor 66
NGS Manufacturer Market Positioning 67
Illumina 68
Thermo-Fisher 72
Roche 76
Pac-Bio 78
Long Read Solutions 82
Other Key Players 83
MGI 84
Oxford Nanopore 88
QIAGEN 93
Genapsys 95
Agilent (LaserGen) 96
NanoString 97
Other Select Players 98
Table of Contents
Executive Summary 13
NGS Market by Customers Type 14
NGS Market by Product Type 15
NGS Market by Application 16
NGS Market by Therapeutic Area 17
NGS Market by Competitor 18
NGS Market Analysis 19
NGS Market by Customer Type 20
NGS Market by Product Type 34
NGS Market by Application 39
NGS Market by Therapeutic Area 47
NGS Market by Geography 62
Appendix 108
NGS Platform Price & Performance 109
Abbreviations 110
Disclosure 113
About DeciBio 114
Key NGS Trends 101
Trends by Customer Type 102
Trends by Product Type 103
Trends by Application 104
Trends by Therapeutic Area 105
Trends by Geography 106
Trends by Competitors 107
6
NGS2019 – 13PFP
5th edition: What’s new?*
Updated Content Key Changes to Market Numbers*
Updated Market Trends
Note: * Selected significant changes only; additional adjustments have been made based on primary and secondary research data analysis
** For this report, we worked under the assumption that the acquisition will go through; if not, the growth prospects of PacBio would be significantly gated, with
some experts believing that the company may be in jeopardy
• Incorporated the latest trends in the NGS manufacturer
market
• Updated market numbers in light of:
o Fast market growth in 2017 and 2018, but more limited
growth in 2019, as reflected on Illumina’s recent results
o Shift in Roche’s expected instrument launch timeline
(ending its agreement with PacBio)
o Progress and adoption for select competitors (e.g.,
Oxford Nanopore, MGI)
o Increased visibility in adoption of novel products (e.g.,
NovaSeq, GridION X5)
• Reassessed market trends for each of the market
segments analyzed, including:
o Customer types (expanded to 11)
o Product and platform types
o Applications and therapeutic areas
o Geographies
• Reevaluated the potential of high-growth applications
o Research applications (e.g., population genomics, single
cell genomics, microbiome research)
o Liquid biopsies (from early detection to monitoring)
• Updated market numbers based on secondary research
and latest trends up to Q2 2019
• Validated and refined our projections of growth rates for key
players, such as:
o Illumina: Market share loss, given increased competitive
intensity (and entrant starting from a low revenue base),
some saturation from high throughput customers, and
exposure to low growth research markets
o Thermo Fisher: Instrument share loss, given expected
competition in clinical decentralized settings, and in light of
the availability of AmpliSeq on Illumina instruments
o Oxford Nanopore (ONT): Excellent recent progress, turning
the corner in Oct. 2016 with the launch of its 9.4 chemistry,
and gaining traction across its product line
o PacBio: Eventful couple of years, but assuming return to
growth following an Illumina acquisition**
• Conducted a new forecast to 2022, taking into
consideration recent and future instrument launches
• Adjusted market size and growth for some markets
o RNA-Seq: Increased growth rate given the rapid adoption of
single cell RNA-Seq
o Therapeutic Area: Increased the relative spend from
oncology (vs. other TAs) customers, given the fast adoption
of liquid biopsy
7
NGS2019 – 13PFP
This report assesses the WW market size, growth and trends of manufacturer
NGS market; it includes and excludes the following solutions
• DNA sample preparation instruments and solutions not
offered by sequencer manufacturers listed to the left
o Single cell prep offerings (e.g., 10X Genomics, Mission Bio)
• DNA fragmentation technologies
o Mechanical shearing (e.g., NGS BioRuptor, Covaris)
o Enzymatic fragmentation (e.g., fragmentase, transposase)
o Chemical fragmentation methods
• DNA mapping technologies
o Various scaffolding technologies (e.g., OpGen,
BioNanogenomics, Nabsys)
• Third party automation or bioinformatics support*
o Liquid handling instrument sales (e.g., Perkin Elmer’s NGS
Express Workstation)
o Hardware (e.g., BioTeam) or Software (e.g., Edico
Genomics) from third party companies
• Sequencing Services
o Clinical service providers (e.g., Sequenom, Illumina Verinata)
o Sequencing Service providers (e.g., Sales from core
facilities)
Note: * Or other forms of third party sales (e.g., companies offering bundled service contracts for multiple lab instrumentation, including NGS)
Source: DeciBio Analysis
Report Scope
• Sequencing instruments from established and emerging
manufacturers, including:
o Illumina
o Thermo Fisher (SOLiD, Ion Torrent)
o Pacific Biosciences
o Roche (454 Life Sciences, Genia)
o MGI
o Oxford Nanopore
o QIAGEN (Intelligent Biosystems)
o Genapsys
• Sequencing reagents and consumables from players listed
above and third party providers (e.g., NEB, ArcherDx)
• Sequencing instrument contract services & software
o Service contract offered by manufacturers to repair the
insured platforms
o Software shipped with the instrument
Technologies and Revenues Included Technologies and Revenues Excluded
8
NGS2019 – 13PFP
Market sizes for each of the top NGS players are reported as instrument or
reagent revenues; Services are excluded from our analysis
Note: * Software typically used for primary analysis (e.g., analysis of raw data coming out of the instrument)
** COGS: Costs of goods sold (which sometimes includes personnel)
Source: DeciBio Analysis
Instruments(Instruments, Service
Contract and Software)
• Instruments include systems used for sample preparation or analysis, and that typically require
a source of energy (e.g., 110V / 220V, battery)
o Example instruments include Illumina’s HiSeq, Ion Torrent’s PGM, PacBio Sequel II, ONT’s MinION
• Many users purchase a service contract (or annual maintenance agreement) to “insure” the
instrument and guarantee timely repair when necessary
o Service contracts typically vary from 10-15% of instrument purchase price (per year)
• Instrument Control and Sequencing Primary Analysis Software* that run the instruments
analyzed in this report
o More advanced hardware (e.g., BioTeam) and software (e.g., DNAnexus) and third part software
are not included in this analysis
Reagents
Product Types
• Reagents and kits are products that are used (in combination or not with an instrument) in
order to analyze a sample
o Example reagents include library preparation kits
Services
(excluded)
• Services are experiments conducted for a lab by a life science research tools manufacturer
(not another laboratory, core facility or CRO)
o Example services include sequencing services from Human Longevity, Foundation Medicine,
Tempus, Guardant Health, university core facilities
o Note: COGS** from service providers are essentially captured by manufacturers included in this report
9
NGS2019 – 13PFP
In this report, we expanded the number of customer types to eleven
Note: * For example, the UK is launching a 500K genome (UK biobank samples) project funded by the government, charities and four biopharma companies
** Applied markets include AgBio, human identification (HID) / forensics, animal health, environmental health, food safety, biosecurity
Source: DeciBio Analysis
Definition Example institutions / logos
Academic Basic
Research
• Non-profit institutions / centers focusing on basic or translational
research, primarily funded by governmental grants (e.g., NIH)
Population Studies• Large initiatives to sequence 10K to 1M patients, typically using
WGS or WES; diverse funding sources exist*
Biopharma R&D• For-profit organizations developing medicines
o This segment tracks preclinical R&D (non-clinical trials)
Biopharma Clinical
Trials
• For-profit organizations developing medicines
o This segment tracks Phase I-III clinical trials (excl. liquid bio)
Liquid Biopsy Clinical
Trials
• Non-profit and for-profit organizations, typically Dx companies,
running clinical trials to launch liquid biopsy tests
Clinical Diagnostics
(Oncology)• Clinical institutions including large and specialized reference
laboratories and hospitals running samples to inform patient
treatment and management
o Oncology (e.g., lung cancer, leukemia)
o NIPT (non-invasive prenatal testing)
o All others (e.g., rare diseases, neurology, cardiology,
preimplantation genetic disease / screening)
Clinical Diagnostics
(NIPT)
Clinical Diagnostics
(All others)
Liquid Biopsy (Dx)• Commercial companies running liquid biopsy tests for applications
such as early cancer detection, or Tx selection / monitoring
Applied Markets• For-profit or government funded institutions and laboratories
running tests in production mode**
Industry• For-profit organization typically offering genomics products to life
science and diagnostics customers
Customer Types
10
NGS2019 – 13PFP
We used a combination of primary and secondary research to compile data
presented in this report
Note: * Overall: 17 interviews in the U.S., 10 in Europe and 5 in the rest of the world
** Discussions started with an assessment of the current and future funding environment
*** Not an exhaustive list; **** Review of blog entries from Dale Yuzuki, James Hadfield, and Keith Robison
Source: DeciBio Analysis
We built a bottom-up market model by competitor; growth rates obtained from interviewee feedback and
secondary research were triangulated with the reality reflecting the current funding environment**
Data and analysis
Primary research Secondary research***
• Interviews with 32 experts*
o 5 academic professors and post-doctoral fellows
from leading institutions worldwide
o 6 lab directors and senior scientists in large Pharma
& small biotechs
o 4 lab directors and scientists in applied markets
o 6 clinical lab directors
o 11 life science business experts / professionals
• Typical interview structure
o Funding
o Current activity
o Key players and technologies
o Trends
o Future activity
• Company financial information
o 10-K / 10-Q and associated earnings call transcripts
o Company presentations
o Press releases
• Company technical information
o Company website
o Company publications and posters
o Company technical sheets
• Other sources
o PubMed Central
o Peer-reviewed publications and scientific posters
o Government reports and databases (e.g., NIH reporter)
o Conferences (e.g., AACR, ASHG)
o Industry observer blog entries****
Key Report Sources
11
NGS2019 – 13PFP
This report is based on rigorous model tracking of expected sales by key
companies and platforms*
Note: * Revenue by platform is DeciBio proprietary information not available in this report. Contact [email protected] for more information
** Numbers shown for demonstration purposes (not real NGS platform data)
*** A simplified version (by company) was used for competitors other than Illumina, Thermo Fisher, Pacific Biosciences, and Roche
Source: DeciBio Analysis
Instrument
Revenues
by Company
Platform
Reagent
Revenues
by Company
Platform
+
=
Total
Revenues
Instrument Revenues Unit Type Year 1 Year 2
Instrument Installed Base
New instrument placement # input 90
Instrument upgrade / trade-in # input 10
Instrument decommission # input 20
Instrument installed base # calc 220 300
Instrument Price
Price per instrument $K input $500
Price per upgrade $K input $100
Price per service contract $K input $60
Instrument Revenues
New instrument revenues $M calc $45
Instrument upgrade revenues $M calc $1
Service contract revenues $M calc $13
Total instrument revenues $M calc $59
Reagent Revenues
Reagent pull-through (new) $M input $200
Reagent pull-through (1+ year) $M calc $350
Total Reagent Revenues $M calc $86
Total Revenues
Total instrument revenues $M feed $59
Total reagent revenues $M feed $86
Total product revenues $M calc $145
Not on
year 1
Linear instrument placement
during the year
Model Approach**
Trade-in
example
• This analysis offers immediate yearly market estimates by:
o Competitor: For example, Illumina or Pacific Biosciences
o Product Type: Instruments vs. reagents
o Platform Type: Workhorse vs. desktop
• This bottoms up analysis is then used to conduct a top down
segmentation as followed***:
o Customer type: Estimated the yearly split for each platform
(e.g., Academic 2019 relative revenues for MiSeq)
o Application: Estimated the yearly split for each platform and
customer type (e.g., RNA-Seq relative revenues for HiSeq
from Academic customers in 2015)
o Geography: Estimated the yearly split for each platform
(done at the company level for some players (e.g., MGI***)
o Therapeutic Area: Estimated the yearly split by customer
type (e.g., oncology split for biopharma customers in 2021)
• These analysis were based on a mix of:
o Platform information and specifications
o Interviewee feedback
o Peer-reviewed publications
o Manufacturer and other websites
o DeciBio expertise
12
NGS2019 – 13PFP
This model highlights how a single platform may generate overall revenue
growth rates of 11% at year 7, as instrument revenues decline in the mid-single
digits at a steady state of 300 instruments sold per year
Note: * Assumptions (2016-2022): Yearly instrument placement: 50, 100, 150, 200, 250, 300, 300; Installed base: 50, 150, 300, 485, 673, 815, 863 (given
some decommission and instrument replacement); Instrument price: $100K (static); Instrument service contract: $10K (static); Percent instrument under
service contract: 90% (static); Reagent pull-through: $50K (static, with 50% at year 1)
Source: DeciBio Analysis
Illustrative NGS Platform*
50
150
300
485
673
815863
-500
-250
0
250
500
0
100
200
300
400
500
600
700
800
900
1,000
2016 2017 2018 2019 2020 2021 2022
Installed Base Instrument Decommission
Instrument Purchase
Installed Base Instrument Purchase / Decommission
2016 2017 2018 2019 2020 2021 2022
Installed Growth - 200% 100% 62% 39% 21% 6%
Purchase Growth - 100% 50% 33% 25% 20% 0%
Decom. Growth - - - - 317% 152% 60%
2016 2017 2018 2019 2020 2021 2022
Instrument Growth - 109% 56% 39% 29% 23% 4%
Reagent Growth - 500% 150% 86% 55% 35% 18%
Overall Growth - 152% 81% 56% 41% 29% 11%
$5 $10
$16 $23
$29 $36 $37
$4
$9
$17
$27
$36 $43
$-
$20
$40
$60
$80
$100
2016 2017 2018 2019 2020 2021 2022
Instruments Reagents
Total Revenues